FDA Approves Alhemo for Patients with Hemophilia

Routine prophylaxis to prevent or reduce bleeding

For Patients with Hemophilia A or B with Inhibitors

The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:

  • Hemophilia A with factor VIII inhibitors, or
  • Hemophilia B with factor IX inhibitors.

What It Is

  • Alhemo is a subcutaneous (under the skin) injection, taken daily.
  • It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.

Effectiveness

  • In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
  • Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.

Safety Info

  • Most common side effects: Injection site reactions and hives.
  • May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
  • Not recommended for patients with serious allergies to the drug or its ingredients.

Special FDA Designations

  • Priority Review
  • Orphan Drug status (for rare conditions)

Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.

More novel drug approvals.

Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.

More approved novel drugs

FDA Alhemo Approval Notice

News

FDA Enforcement

Safety Alerts

Medical Devices

Pharma

New Drugs

Drug Shortages

Plastic Syringe Safety: FDA’s Ongoing Evaluation

Today, the U.S. Food and Drug Administration (FDA) provided a crucial update regarding the quality and performance issues associated with plastic syringes made in China. This announcement follows the agency's previous safety communication issued on November 30, 2023,...

Original FDA Safety Warning for China-made Syringes

In an announcement dated November 30, 2023, the U.S. Food and Drug Administration (FDA) issued a notice regarding the evaluation of potential device failures associated with plastic syringes manufactured in China. The FDA is actively collecting and analyzing data to...

AvKARE Recalls Atovaquone Oral Suspension

AvKARE Recalls Atovaquone Oral Suspension  AvKARE, LLC has issued a voluntary recall of lot # AW0221A of Atovaquone Oral Suspension, USP 750mg/5mL due to potential Bacillus cereus contamination found during stability testing at a third-party lab.   The affected...